Vice President, Clinical Development at Alector

United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

MD or MD/PhD with at least 10 years of clinical drug development experience
Proven track record leading programs in rare diseases and CNS, or alternatively, in neurodegenerative disease
Demonstrated success bringing therapies through late-stage development, US FDA interactions and filing, and drug launch, including serving as the point-person leading filings with the FDA
Experience working independently and cross-functionally in fast-paced, matrixed environments, with ability to influence cross-functional colleagues
Active user of large language models (LLMs) with a strong interest in evolving AI applications in clinical development and commercialization-readiness

Responsibilities

Serve as lead clinical expert for the Phase 3 Frontotemporal Dementia (FTD) program following data readout, driving all clinical strategies and partnering on regulatory activities to enable filing
Lead strategic and operational engagement with the US FDA, including participation in key meetings and authorship of major regulatory submissions
Own the clinical development plan from late-stage study execution through potential BLA filing and NDA approval
Provide clinical insights that guide program decisions, ensuring scientific rigor, patient safety, and regulatory compliance at every step
Integrate innovative technologies—including AI—to accelerate timelines and improve decision-making across development stages
Work cross-functionally with Clinical Operations, Regulatory Affairs, Biometrics, and Commercial colleagues to achieve the mission of delivering transformative therapies

Skills

Clinical Development

Phase 3 Trials

FDA Regulatory

Regulatory Submissions

Clinical Operations

Regulatory Affairs

Biometrics

Neurodegeneration

Frontotemporal Dementia

Alector

Develops therapies for neurodegenerative diseases

About Alector

Alector develops therapies aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's. The company focuses on research and development of new drug candidates by utilizing knowledge from immunology, neurology, and human genetics. Their approach involves conducting early-stage clinical trials to gather specific data about diseases, which helps improve the chances of success for their treatments. Alector differentiates itself from competitors by emphasizing the body's natural healing processes in their drug development. The company's goal is to create effective treatments for conditions that currently have limited options, while also attracting funding and partnerships through their research findings.

San Francisco, CaliforniaHeadquarters

2013Year Founded

$189.2MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Risks

Failure in AL002 trial may decrease investor confidence and financial stability.

Reliance on external financing increases financial risk if therapies don't succeed commercially.

Increased competition in neurodegenerative market could impact Alector's market share.

Differentiation

Alector combines antibody technology with neuroimmunology for novel neurodegenerative therapies.

Strategic alliance with Adimab enhances Alector's antibody discovery and optimization capabilities.

Focus on genetically validated therapies aligns with personalized medicine trends.

Upsides

Increased interest in neuroimmunology boosts investment and collaboration opportunities for Alector.

AI-driven drug discovery enhances efficiency, aligning with Alector's technology-driven strategy.

Expansion of strategic alliances offers collaboration and resource sharing opportunities for Alector.

Land your dream remote job 3x faster with AI

Try Jobo Free